Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $222.50 USD
Change Today +0.43 / 0.19%
Volume 384.9K
SHPG On Other Exchanges
Symbol
Exchange
SHPG is not on other exchanges.
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5 Riverwalk

Citywest Business Campus

Dublin, 24

Ireland

Phone: 353 1 429 7700

Fax:

r Human Immunodeficiency Virus and Hepatitis B virus. In the United States, royalty terms expire between 2015 and 2018. ADHD ADDERALL XR The company receives royalties from Impax’s sales of its authorized generic version of ADDERALL XR. INTUNIV Commencing December 1, 2014, the company is entitled to royalties from Actavis’ sales of its generic version of INTUNIV. Hyperphosphatemia FOSRENOL The company licensed the rights to FOSRENOL in Japan to Bayer in 2003. Bayer launched FOSRENOL in Japan in 2009. The company receives royalties from Bayer’s sales of FOSRENOL in Japan. Other Royalties The company has licensed the rights to certain other products to third parties and receives royalties on third party sales. Products Under Development The company focuses its development resources on projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology and gastrointestinal, and focuses its early development projects primarily on rare diseases. Products in Registration as of December 31, 2014 INTUNIV for the Treatment of ADHD in the EU In March 2014, the company announced the acceptance of submission of a MAA by the EMA for once-daily, non-stimulant guanfacine extended release for the treatment of ADHD in children/adolescents aged 6-17 years. VYVANSE for the Treatment of BED In 2013, the company reported positive top-line results from two identically designed randomized placebo-controlled Phase 3 studies evaluating the efficacy and safety of VYVANSE versus placebo in adults with BED. In both studies VYVANSE was found to be statistically superior to placebo on the primary efficacy analysis (p-value <0.001) of the change from baseline at weeks 11 to 12 in terms of number of binge days per week. The safety for VYVANSE in these two studies appears to be generally consistent with the known profile established in studies in adults with ADHD. In 2014, the company announced that the FDA had accepted for filing with priority review a sNDA for VYVANSE as a treatment for adults with BED. On January 30, 2015 the FDA approved VYVANSE for the treatment of moderate to severe BED in adults. Products in Registration as of December 31, 2014 INTUNIV for the Treatment of ADHD in the EU In 2014, the company announced the acceptance of submission of a MAA by the EMA for once-daily, non-stimulant guanfacine extended release for the treatment of ADHD in children/adolescents aged 6-17 years. VYVANSE for the Treatment of BED In January 2015 the FDA approved VYVANSE for the treatment of moderate to severe BED in adults. Products in Clinical Development as of December 31, 2014 Phase 3 and Phase 3-ready SHP606 (lifitegrast) for the treatment of DED: Following a meeting with the FDA, on May 16, 2014, the company announced that it intends to submit an NDA for SHP606 in the first quarter of 2015 as a treatment for the signs and symptoms of DED in adults. SHP465 for the treatment of ADHD in adults: SHP465 (mixed salts of a single entity amphetamine) capsules provide an extended-release of amphetamines to provide coverage of ADHD symptoms for adults throughout the day. FIRAZYR for the treatment of ACE-I AE: A Phase 3 clinical trial to assess the efficacy of FIRAZYR for the treatment of ACE-I AE was initiated in 2013 and is ongoing. FIRAZYR for the treatment of HAE in Japan: The company plans to initiate a Phase 3 trial to evaluate the efficacy and safety of FIRAZYR for the treatment of HAE in Japanese patients in 2015. SHP555 (prucalopride; marketed as RESOLOR in the EU) for the treatment of chronic constipation in the United States: The company owns the rights to develop and market prucalopride in the United States in an agreement with Janssen Pharmaceutica N.V. INTUNIV for the treatment of ADHD in Japan: Under a collaboration agreement, Shionogi and the company would co-develop and sell treatments for ADHD in Japan, including INTUNIV. A Phase 3 clinical program to evaluate the efficacy and safety of INTUNIV in Japanese patients aged 6 to 17 was initiated in 2013. SHP616 (CINRYZE) for routine prophylaxis against HAE attacks in adoles

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHPG:US $222.50 USD +0.43

SHPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$90.18 AUD +0.16
Eisai Co Ltd ¥7,776 JPY -164.00
Mylan NV $48.05 USD +0.63
Perrigo Co PLC $178.80 USD +0.85
View Industry Companies
 

Industry Analysis

SHPG

Industry Average

Valuation SHPG Industry Range
Price/Earnings 14.4x
Price/Sales 7.1x
Price/Book 4.8x
Price/Cash Flow 13.7x
TEV/Sales 7.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC-ADR, please visit www.shire.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.